Breakthrough therapy designation to capmatinib- Lung Cancer

The FDA granted breakthrough therapy designation to capmatinib for first-line treatment of metastatic MET exon 14 skipping-mutated non-small cell lung cancer. MET mutations — identified in approximately 4% of patients with NSCLC — are associated with poor prognosis. The mutations, typically seen among older patients, can limit treatment options. No targeted therapies are approved to …


Recent Trends in Oncology

Research shows that patients with metastatic colorectal cancer who exercised regularly achieved longer PFS than those who did not. Learn more about oncology at: